H U V Aisiri, Rao Maanas R, Ramani Vinod K, Naik Radheshyam
Department of Biotechnology, Rashtreeya Vidyalaya (RV) College of Engineering, Bangalore, India.
Preventive Oncology, Sammprada Cancer Hospital, Bangalore, India.
Front Oncol. 2025 Jul 15;15:1615491. doi: 10.3389/fonc.2025.1615491. eCollection 2025.
Diabetes mellitus (DM) is frequently diagnosed among cancer patients on treatment, which suggests a concomitant underlying mechanism. DM is found among 8 to 18% of cancer patients. The initiation of cancer treatment is linked with the onset of diabetes. This study aims to assess the variation in blood glucose levels of cancer patients during the course of their treatment.
A hospital record based cross-sectional study was conducted from November 2024 to January 2025, among 50 cancer patients on treatment at Sammprada cancer hospital, Bangalore, India. From the initial 50 cancer patients, a series of 11 cases with large variation in blood glucose levels were included in the study. These include new onset or old cases of diabetes, with blood glucose levels measured across 6 timeframes during the course of cancer treatment.
For the initial 50 patients, the measure of central tendency seemed regressed to the mean. Hence, the design of study was changed from cross-sectional to a case series. For the series of 11 patients all of whom had advanced stage cancer, 5 patients (2 males, 3 females) had history of diabetes and 2 female patients were incident cases of diabetes (1 each in endocrine and cervical cancer). Also, the treatment for diabetes was revised or newly initiated for a total of 5 patients (4 females, 1 male).
Among the 11 cancer patients, 5 had history of DM and 2 were incident cases of DM. Healthcare providers should regularly screen the levels of blood glucose during the continuum of cancer care and monitor the change in trend.
糖尿病（DM）在接受治疗的癌症患者中经常被诊断出来，这表明存在潜在的共同机制。在8%至18%的癌症患者中发现患有糖尿病。癌症治疗的开始与糖尿病的发病有关。本研究旨在评估癌症患者在治疗过程中血糖水平的变化。
2024年11月至2025年1月，在印度班加罗尔的Sammprada癌症医院对50名正在接受治疗的癌症患者进行了一项基于医院记录的横断面研究。从最初的50名癌症患者中，选取了11例血糖水平差异较大的病例纳入研究。这些病例包括新发病例或糖尿病旧病例，在癌症治疗过程中跨越6个时间框架测量血糖水平。
对于最初的50名患者，集中趋势测量似乎回归到均值。因此，研究设计从横断面研究改为病例系列研究。对于这11例均为晚期癌症的患者，5例（2例男性，3例女性）有糖尿病病史，2例女性患者为糖尿病新发病例（内分泌癌和宫颈癌各1例）。此外，共有5例患者（4例女性，1例男性）的糖尿病治疗方案进行了修订或新开始治疗。
在这11名癌症患者中，5例有糖尿病病史，2例为糖尿病新发病例。医疗服务提供者应在癌症治疗的全过程中定期筛查血糖水平，并监测趋势变化。
